Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 10/20 | 0.60 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.60 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366778 | 0.97 | HCRTR1 (0.58) | HCRTR1HCRTR2USP30DPP4HSD11B1 | |
| SCHEMBL3369475 | 0.90 | HCRTR1 (0.61) | HCRTR1HCRTR2USP30DPP4HSD11B1 | |
| SCHEMBL3366768 | 0.89 | HCRTR1 (0.57) | HCRTR1HCRTR2USP30DPP4HSD11B1 | |
| SCHEMBL3659576 | 0.89 | HCRTR1 (0.50) | HCRTR1HCRTR2USP30DPP4HSD11B1 | |
| SCHEMBL3368236 | 0.88 | ALDH1A1 (0.56) | HCRTR1HCRTR2USP30RAB9ASCD | |
| SCHEMBL3366901 | 0.87 | HCRTR1 (0.61) | HCRTR1HCRTR2USP30DPP4HSD11B1 | |
| SCHEMBL3366080 | 0.86 | HCRTR1 (0.55) | HCRTR1HCRTR2USP30DPP4HSD11B1 | |
| SCHEMBL4955786 | 0.85 | ALDH1A1 (0.60) | HCRTR1HCRTR2TSHR | |
| SCHEMBL4955775 | 0.85 | ALDH1A1 (0.60) | HCRTR1HCRTR2TSHR | |
| SCHEMBL3368150 | 0.84 | HCRTR1 (0.67) | HCRTR1HCRTR2USP30NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-05-11 | — | — | US | disclosed |
| EP-1532141-B1 | 2-PYRROLIDIN-2-YL- [1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS | GRUENENTHAL GMBH (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-7105538-B2 | 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2006-09-12 | — | — | US | disclosed |
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | OPRD1, OPRK1, GRIN2C | HCRTR1 461/4885HCRTR2 146/4885USP30 3920/4885 |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PREP | HCRTR1 3869/4885HCRTR2 4436/4885USP30 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.